Noonan Syndrome Clinical Trial
Official title:
Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome and to Identify Predictive Factors of Disease Progression
The present study will establish a collection of biological samples from Noonan patients to be used for research purposes only, with due respect for confidentiality.
Noonan syndrome is a rare autosomal dominant genetic disorder characterized by a combination of typical facial features, heart defects, short stature, skeletal abnormalities, mild developmental delay and a predisposition to myeloproliferative disorders. This syndrome is caused by germline mutations in genes encoding components or regulators of the Rat Sarcoma (RAS) / extracellular signal-regulated kinase (ERK) signaling pathway, which is essential for cell cycle differentiation, growth, and senescence. Patients with Noonan syndrome or related diseases are followed at the children's hospital, Toulouse University Hospital. During regular check-up visits, an extra sample of blood and urine will be collected and stored for research utilisation with the patient's consent. The ultimate objective of this collection is to provide available biological resources to facilitate the development of subsequent studies aimed at better characterizing the multisystemic disorders in Noonan syndrome, to understand the pathophysiology of the disease, and to identify biological factors that predict the severity and progression of the disease. The possibility of having systematically collected biological resources will make it possible to answer certain questions more quickly depending on the progress of research. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
| Completed |
NCT00452725 -
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
|
Phase 3 | |
| Recruiting |
NCT05761314 -
Solid Tumors in RASopathies
|
N/A | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
| Enrolling by invitation |
NCT05308927 -
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
|
||
| Recruiting |
NCT04395495 -
RASopathy Biorepository
|
||
| Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT06355622 -
Prevalence and Characterization of Pain in RASopathies
|
N/A | |
| Completed |
NCT02713945 -
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT05361811 -
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
|
N/A | |
| Completed |
NCT03435627 -
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
|
||
| Recruiting |
NCT05723835 -
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
|
Phase 3 | |
| Completed |
NCT02486731 -
Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes
|
||
| Completed |
NCT01927861 -
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT04888936 -
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
|
||
| Recruiting |
NCT06331117 -
Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies
|
N/A | |
| Completed |
NCT00960128 -
Observational Prospective Study on Patients Treated With Norditropin®
|
N/A | |
| Terminated |
NCT00351221 -
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
|
Phase 2 |